NASDAQ:TMDX TransMedics Group (TMDX) Stock Price, News & Analysis $108.12 +1.33 (+1.25%) Closing price 04:00 PM EasternExtended Trading$107.60 -0.52 (-0.48%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About TransMedics Group Stock (NASDAQ:TMDX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get TransMedics Group alerts:Sign Up Key Stats Today's Range$105.06▼$108.6650-Day Range$103.61▼$143.0452-Week Range$55.00▼$177.37Volume652,618 shsAverage Volume916,207 shsMarket Capitalization$3.66 billionP/E Ratio79.50Dividend YieldN/APrice Target$129.88Consensus RatingModerate Buy Company Overview TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts. Read More TransMedics Group Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreTMDX MarketRank™: TransMedics Group scored higher than 42% of companies evaluated by MarketBeat, and ranked 682nd out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingTransMedics Group has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageTransMedics Group has only been the subject of 4 research reports in the past 90 days.Read more about TransMedics Group's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth43.00% Earnings GrowthEarnings for TransMedics Group are expected to grow by 43.00% in the coming year, from $1.00 to $1.43 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TransMedics Group is 79.50, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.91.Price to Earnings Ratio vs. SectorThe P/E ratio of TransMedics Group is 79.50, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.11.Price to Book Value per Share RatioTransMedics Group has a P/B Ratio of 15.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about TransMedics Group's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted25.56% of the float of TransMedics Group has been sold short.Short Interest Ratio / Days to CoverTransMedics Group has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in TransMedics Group has recently increased by 2.29%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTransMedics Group does not currently pay a dividend.Dividend GrowthTransMedics Group does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted25.56% of the float of TransMedics Group has been sold short.Short Interest Ratio / Days to CoverTransMedics Group has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in TransMedics Group has recently increased by 2.29%, indicating that investor sentiment is decreasing. News and Social Media2.4 / 5News Sentiment1.30 News SentimentTransMedics Group has a news sentiment score of 1.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.06 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for TransMedics Group this week, compared to 18 articles on an average week.Search InterestOnly 12 people have searched for TMDX on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added TransMedics Group to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, TransMedics Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,512,613.00 in company stock.Percentage Held by InsidersOnly 7.00% of the stock of TransMedics Group is held by insiders.Percentage Held by Institutions99.67% of the stock of TransMedics Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about TransMedics Group's insider trading history. Receive TMDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TransMedics Group and its competitors with MarketBeat's FREE daily newsletter. Email Address TMDX Stock News HeadlinesWhy TransMedics Remains A Buy Into 2026July 25 at 12:12 PM | seekingalpha.comCanaccord Genuity Group Issues Positive Forecast for TransMedics Group (NASDAQ:TMDX) Stock PriceJuly 18, 2025 | americanbankingnews.comBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the country are buzzing in anticipationJuly 25 at 2:00 AM | Crypto 101 Media (Ad)TransMedics to Report Second Quarter 2025 Financial Results on July 30, 2025July 16, 2025 | prnewswire.comTransMedics: Q2 Analyst Estimates Will Fall ShortJuly 14, 2025 | seekingalpha.comTMDX - TransMedics Group Inc Executives - MorningstarJuly 5, 2025 | morningstar.comMTransMedics Group, Inc. (TMDX) Cash Flow - Yahoo FinanceJuly 4, 2025 | finance.yahoo.comIs TransMedics Stock a Buy After Short-Seller Drama?July 3, 2025 | fool.comSee More Headlines TMDX Stock Analysis - Frequently Asked Questions How have TMDX shares performed this year? TransMedics Group's stock was trading at $62.35 at the beginning of 2025. Since then, TMDX shares have increased by 73.4% and is now trading at $108.12. How were TransMedics Group's earnings last quarter? TransMedics Group, Inc. (NASDAQ:TMDX) posted its quarterly earnings data on Thursday, May, 8th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.29 by $0.41. The firm's quarterly revenue was up 48.2% compared to the same quarter last year. Read the conference call transcript. When did TransMedics Group IPO? TransMedics Group (TMDX) raised $75 million in an initial public offering on Thursday, May 2nd 2019. The company issued 4,700,000 shares at $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers. Who are TransMedics Group's major shareholders? Top institutional investors of TransMedics Group include Zevenbergen Capital Investments LLC (0.36%), Blair William & Co. IL (0.20%), Taylor Frigon Capital Management LLC (0.06%) and State of Alaska Department of Revenue (0.06%). Insiders that own company stock include James R Tobin, Waleed H Hassanein, Miriam Provost, Stephen Gordon, Nicholas Corcoran, Tamer I Khayal, John F Carey, Anil P Ranganath, David Weill, Edward M Basile, Stephanie Lovell and Laura Damme. View institutional ownership trends. How do I buy shares of TransMedics Group? Shares of TMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of TransMedics Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that TransMedics Group investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Invesco QQQ (QQQ), Broadcom (AVGO), Arista Networks (ANET) and CrowdStrike (CRWD). Company Calendar Last Earnings5/08/2025Today7/25/2025Next Earnings (Estimated)7/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:TMDX CIK1756262 Webwww.transmedics.com Phone(978) 552-0900FaxN/AEmployees210Year FoundedN/APrice Target and Rating Average Price Target for TransMedics Group$129.88 High Price Target$178.00 Low Price Target$75.00 Potential Upside/Downside+20.1%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)$1.36 Trailing P/E Ratio79.50 Forward P/E Ratio108.12 P/E GrowthN/ANet Income$35.46 million Net Margins10.03% Pretax Margin10.25% Return on Equity21.88% Return on Assets6.15% Debt Debt-to-Equity Ratio1.92 Current Ratio9.10 Quick Ratio8.32 Sales & Book Value Annual Sales$441.54 million Price / Sales8.28 Cash Flow$1.62 per share Price / Cash Flow66.83 Book Value$6.81 per share Price / Book15.88Miscellaneous Outstanding Shares33,820,000Free Float31,456,000Market Cap$3.66 billion OptionableOptionable Beta2.06 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:TMDX) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransMedics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransMedics Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.